Bouwmeester, R. N., Duineveld, C., Wijnsma, K. L., Bemelman, F. J., van der Heijden, J. W., van Wijk, J. A. E., Bouts, A. H. M., van de Wetering, J., Dorresteijn, E., Berger, S. P., Gracchi, V., van Zuilen, A. D., Keijzer-Veen, M. G., de Vries, A. P. J., van Rooij, R. W. G.
, Engels, F. A. P. T., Altena, W., de Wildt, R., van Kempen, E., ... Atypical Hemolytic Uremic Syndrome working group (2022).
Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study.
Kidney International Reports,
8(1), 91-102.
https://doi.org/10.1016/j.ekir.2022.10.013